A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus (T2DM)

In brief

The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM

Key facts

Study ID

NCT07465224

Run by

Alnylam Pharmaceuticals

People needed

24

Starts

2026-01-15

Expected to finish

2027-05-28

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Is an adult patient with a confirmed diagnosis of T2DM
• Has a body mass index (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2
• Has a hemoglobin A1c (HbA1c) ≥6.5% to <10.5%
• Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i)

You may not qualify if…

• Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
• Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods
• Note: other protocol defined inclusion/exclusion criteria apply

Where it is running

• Clinical Trial Site — Chula Vista, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.